Isozid N (Isoniazid)

Isoniazid inhibits the enzyme enoyl‑ACP reductase (InhA), blocking the synthesis of mycolic acids that are vital for the mycobacterial cell wall. This disruption compromises cell integrity and leads to bacterial death, especially in actively replicating Mycobacterium tuberculosis.

The appropriate dose of Isozid N is determined by the prescribing clinician based on the patient’s clinical condition, weight, renal function, and treatment protocol. Specific dosing regimens are not provided here and should follow the prescriber’s instructions.

Isoniazid is classified as Pregnancy Category C, indicating that it should be used only when the potential benefits justify the potential risks to the fetus. Caution is advised during breastfeeding, and a healthcare professional should evaluate the risk‑benefit balance.

To order Isozid N, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Isoniazid is a first‑line antitubercular agent, often used in combination with rifampin, pyrazinamide, and ethambutol. Compared with rifampin, isoniazid has a different mechanism—targeting mycolic acid synthesis— and a distinct side‑effect profile, with a higher incidence of peripheral neuropathy and hepatotoxicity but less drug‑inducing orange bodily fluids.

Isozid N should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light. Ensure that the container remains sealed until use and that any reconstituted solution is administered promptly according to aseptic technique.

Isozid N is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are determined by the prescribing clinician, and the medication should be administered using sterile equipment in a clinical setting.

The most serious risks include hepatotoxicity, which may present as jaundice or elevated liver enzymes, and severe peripheral neuropathy that can lead to functional impairment. Rare but critical reactions such as anaphylaxis, Stevens‑Johnson syndrome, and drug‑induced lupus‑like syndrome also require immediate medical attention.

Isozid N is contraindicated in patients with known hypersensitivity to isoniazid or any of its excipients, and in individuals with severe acute liver disease. Caution is also advised for patients with pre‑existing peripheral neuropathy, pregnant women unless clearly indicated, and those taking medications that strongly induce hepatic enzymes without appropriate monitoring.